Company
BioCryst Pharmaceuticals
NASDAQ:BCRX
BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company that designs, optimizes and develops novel drugs that block enzymes involved in cancer, viral infections and autoimmune diseases.
11 stories
BioCryst Pharmaceuticals shares crash despite reaching primary endpoint in Phase 3 trial for heart drug
The trial of the once-daily compound BCX7353 achieved its primary endpoint for both dose levels of 110 mg and 150 mg, the firm said
EARLY MOVERS: CBS shares move on expected departure of CEO Les Moonves while G-III Apparel Group shares hitch higher before the bell
Also, in pre-market New York trade, Netflix was bouncing back, but ProQR Therapeutics NV plunged.
BioCryst Pharmaceuticals and Idera call it quits on merger
BioCryst shareholders voted overwhelmingly to torpedo the deal
BioCryst Pharmaceuticals and Idera to merge and advance clinical programmes
Together the companies will have two Phase 3 and two Phase 2 drug candidates, and it was highlighted that there would be several important catalysts in 2018.
Biocryst Pharmaceuticals shares swell on positive clinical trial findings
The study is a 3-part dose ranging trial evaluating the oral inhibitor
US stocks finish higher but big oilers skid
Wall Street shares finished higher on Wednesday....
Dramatic Wall St falls buttressed by bargain hunters
After a bruising session where energy and tech stocks led declines on growth fears and weaker oil prices, Wall Street tickers managed to halve losses on bargain-hunting late on Monday
Trending - Today's unfounded big pharma merger rumor is ...
A whisper to a scream ... rumors of another big pharma merger are gaining volume
Drug trial blows up in BioCryst's face
BioCryst Pharmaceuticals faced an exit by investors on Monday as news of failure in trials of a new drug for a rare genetic disorder wiped two-thirds off its share price
Energy and tech stocks drag Wall Street down
After a shocker of an open, the best that can be said is that things did not get much worse